文献速递其他结缔组织病

系统性硬化症患者在干预性随机试验中的代表性:EUSTAR数据库分析

Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

基于EUSTAR数据库8046例系统性硬化症(SSc)患者,评估其符合2013-2018年注册的37项干预性随机对照试验(RCT)入选标准的比例及不合格原因。

要点

  • 治疗和安全性相关标准是患者招募的主要障碍,而非人口学特征。
  • 高龄、无雷诺现象和较低mRSS独立关联于不符合任何试验标准。

核心结论

  • SSc患者在RCT中的代表性高度可变,主要由治疗和安全性相关标准而非人口学标准驱动。

研究设计与样本

  • 检索ClinicalTrials.gov 2013年1月至2018年1月注册的干预性SSc-RCT,由两名评价者筛选并提取试验特征。
  • 使用EUSTAR数据库中自2013年以来有访视记录的8046例患者数据评估合格性,进行完整病例、最差和最佳情况分析。

主要发现

  • 纳入37项RCT,43%在欧洲进行,35%由工业资助,87%研究药物治疗。
  • 完整病例分析中,针对主要器官并发症的合格患者比例中位数为60%(范围10-100%)。
  • 针对皮肤纤维化的试验合格比例中位数为50%(范围32-79%),针对雷诺现象的试验为90%(范围34-77%)。
  • 高龄、无雷诺现象和较低mRSS独立关联于不符合任何纳入试验的标准。

关键数值与推荐

  • 针对主要器官并发症的合格患者比例中位数为60%(范围10-100%)。
  • 针对皮肤纤维化的试验合格比例中位数为50%(范围32-79%)。
  • 针对雷诺现象的试验合格比例中位数为90%(范围34-77%)。

临床怎么用

  • 解读SSc-RCT结果时需考虑试验人群代表性有限,治疗和安全性标准可能排除大量真实世界患者。
  • 在设计或招募SSc试验时,应评估治疗和安全性标准的宽严对代表性和外推性的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the extent of and the reasons for ineligibility in randomized controlled trials (RCTs) of SSc patients included in the EUSTAR database, and to determine the association between patient's features and generalizability of study results. METHODS: We searched Clinicaltrials.gov for all records on interventional SSc-RCTs registered from January 2013 to January 2018. Two reviewers selected studies, and information on the main trial features were retrieved. Data from 8046 patients having a visit in the EUSTAR database since 2013 were used to check patient's eligibility. The proportion of potentially eligible patients per trial, and the risk factors for ineligibility were analysed. Complete-, worst- and best-case analyses were performed. RESULTS: Of the 37 RCTs included, 43% were conducted in Europe, 35% were industry-funded, and 87% investigated pharmacological treatments. Ninety-one percent of 8046 patients included could have participated in at least one RCT. In complete-case analysis, the median [range] proportion of eligible patients having the main organ complication targeted by each study was 60% [10-100] in the overall sample of trials, ranging from 50% [32-79] for trials on skin fibrosis to 90% [34-77] for those targeting RP. Among the criteria checked, treatment- and safety-related but not demographic were the main barriers to patient's recruitment. Older age, absence of RP, and lower mRSS were independently associated with the failure to fulfill criteria for any of the included studies. CONCLUSIONS: Patient's representativeness in SSc-RCTs is highly variable and is driven more by treatment- and safety-related rather than demographic criteria.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Iudici M, Jarlborg M, Lauper K, et al. Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology (Oxford). 2022. PMID: 33989387. doi:10.1093/rheumatology/keab437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。